Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Inclusion Criteria:

* Pathologic or cytologic diagnosis of solid tumors or lymphoma
* Metastatic disease

  * No curative or effective therapy exists
* Measurable or nonmeasurable disease
* No clinically relevant third-space fluid collections

  * Fluid collections must be drained before study enrollment
* No leukemia
* No CNS metastases

Exclusion Criteria:

* ECOG performance status 0-2
* Life expectancy ≥ 12 weeks
* ANC ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9 g/dL
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)
* Creatinine clearance ≥ 45 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study therapy
* No active infection or other serious illness that would preclude study participation
* No weight loss ≥ 10% within the past 6 weeks
* No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1
* Must be able to take concurrent vitamin B12 and folic acid

PRIOR CONCURRENT THERAPY:

* No more than 1 prior chemotherapy regimen for metastatic disease
* More than 12 months since prior adjuvant therapy
* More than 30 days since prior drug that has not received regulatory approval
* More than 30 days since prior radiation therapy and recovered (alopecia allowed)
* Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed
* No prior radiation therapy to ≥ 25% of bone marrow
* No prior oxaliplatin or pemetrexed disodium
* No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents \[e.g., piroxicam\]), during, and for 2 days after each dose of pemetrexed disodium
* No concurrent nonpalliative radiation therapy or surgery for cancer
* No concurrent hormonal cancer therapy (except medroxyprogesterone)
* No other concurrent experimental medications (except thymidine)
* No other concurrent chemotherapy or immunotherapy
* No other concurrent anticancer therapy
* Concurrent palliative radiation therapy allowed for small areas of painful metastasis that cannot be managed adequately by systemic or local analgesics